The 43rd Annual San Antonio Breast Cancer Symposium, SABCS 2020 will be held Virtually, December 8 – 12, 2020.

Presentations:

• Fam- deruxtecan-nxki (Enhertu) Daiichi Sankyo/Astra Zeneca • Patritumab Deruxtecan (U3-1402; HER3-DXd) Daiichi Sankyo/Astra Zeneca

Abstract Presentation Details Fam--nxki (Enhertu) Daiichi Sankyo/Astra Zeneca Updated results from DESTINY-Breast01, a phase 2 trial Spotlight Poster Discussion 3 of trastuzumab deruxtecan in HER2 positive metastatic (Abstract 1190; PD3-06) breast cancer Modi, et al. Advances in the Treatment of HER2+ Disease;

Wednesday, December 9, 2020 at 6:30 pm CT Trastuzumab deruxtecan with in patients with Spotlight Poster Discussion 3 HER2 expressing advanced breast cancer: a two-part, (Abstract 299; PD3-07) phase 1b, multicenter, open-label study Hamilton, et al. Advances in the Treatment of HER2+ Disease;

Wednesday, December 9, 2020 at 6:30 pm CT Novel approach to HER2 quantification: digital pathology Spotlight Poster Discussion 6 coupled with AI-based image and data analysis delivers (Abstract 1130; PD6-01) objective and quantitative HER2 expression analysis for enrichment of responders to T-DXd, specifically in HER2 Gustavson, et al. Novel Approaches low patients to Pathology and Imaging;

Thursday, December 10, 2020 at 3:30 pm CT Trastuzumab deruxtecan vs. in Poster Presentation (Abstract 323; high risk patients with HER2 positive, residual invasive OT-03-01) early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05) Geyer, et al. Ongoing Trials Poster;

[Trial in Progress] Wednesday, December 9, 2020 at 8:00 am CT Page 1 of 2

Trastuzumab deruxtecan vs. investigator’s choice Poster Presentation (Abstract 1219; chemotherapy in patients with hormone receptor positive, OT-03-09) HER2 low metastatic breast cancer whose disease has progressed on endocrine therapy in the metastatic setting: Bardia, et al. Ongoing Trials Poster; a randomized, phase 3 trial (DESTINY-Breast06) Wednesday, December 9, 2020 at [Trial in Progress] 8:00 am CT Trastuzumab deruxtecan combinations in patients with Poster Presentation (Abstract 428; HER2 positive advanced or metastatic breast cancer: a OT-03-04) phase 1b/2 open-label, multicenter, dose finding and dose expansion study (DESTINY-Breast07) Andre, et al. Ongoing Trials Poster;

[Trial in Progress] Wednesday, December 9, 2020 at 8:00 am CT Trastuzumab deruxtecan combinations in patients with Poster Presentation (Abstract 532; HER2 low metastatic breast cancer: a phase 1b open- OT-03-05) label, multicenter, dose finding and expansion study (DESTINY-Breast08) Jhaveri, et al. Ongoing Trials Poster; [Trial in Progress] Wednesday, December 9, 2020 at 8:00 am CT Poster Presentation (Abstract 426; PS7-82) A real-world evidence study of treatment patterns among patients with HER2 positive metastatic breast cancer Collins, et al. Epidemiology; (mBC) Wednesday, December 9, 2020 at 8:00 am CT Patritumab Deruxtecan (HER3 ADC) Daiichi Sankyo/Astra Zeneca Safety and efficacy results from the phase 1/2 study of Spotlight Poster Discussion 1 U3-1402, a human epidermal receptor 3 (Abstract 814; PD1-09) (HER3) directed antibody drug conjugate (ADC), in patients with HER3 expressing metastatic breast cancer Krop, et al. Novel Therapeutics; (MBC) Wednesday, December 9, 2020 at 4:00 pm CT

Last update: December 1, 2020

Page 2 of 2